Make us your home page
Instagram

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

M2Gen partnership advances Moffitt Cancer Center vision for personalized medicine

TAMPA — Moffitt Cancer Center's ambitions to become a leader in personalized cancer treatment advanced this week with the announcement of a new research partner with global reach.

M2Gen, the cancer center's for-profit research subsidiary, has signed a deal with Covance Inc. to develop cancer drugs by tapping into its extensive database of patient information.

M2Gen has collected about 35,000 tumor samples, stored in freezers on its north Tampa campus. About half have been analyzed for unique genetic markers that could become potent targets for cancer therapies.

M2Gen sees its database of genetic and clinical information — one of the largest of its kind — as a way to accelerate bringing new drugs to the market. It has been trying to develop a business model around identifying the patients most likely to benefit from the therapies and matching them to clinical trials.

"No one institution can do everything," said Dr. Bill Dalton, who last year stepped down as Moffitt's president and CEO to lead M2Gen. "By working with places like Covance, we can start developing new therapies that aren't available yet."

He declined to disclose financial terms of the deal with Covance, a publicly traded company based in Princeton, N.J., that describes itself as one of the world's largest and most comprehensive drug development services companies.

M2Gen's information can help design clinical trials and place patients into them, but actually running the trials is outside of its scope, Dalton said. That's where Covance comes in.

Covance will have the exclusive rights to market its trial-matching services with M2Gen. The partnership can be extended beyond its initial three years.

The concept is a new model for M2Gen, which launched in 2007 with the promise of breaking scientific ground while creating high-paying biotech jobs. More than $35 million in public dollars have been invested.

Initially, it had an exclusive partnership with drug giant Merck, which bankrolled nearly $100 million — the majority of the venture. But that deal expired after five years. Dalton said M2Gen and Merck continue to work together on a project-by-project basis.

Now M2Gen considers itself a "health information solution company," Dalton said. It has three trials running in the clinical trial matching business that it is trying to build. Nearly a dozen more are under development.

Under its arrangement with Covance, M2Gen can work directly with Merck and other pharmaceutical companies, Dalton said.

He declined to comment on M2Gen's profitability. But according to a report filed by Moffitt for bondholders, M2Gen posted a $2.3 million loss on $6.3 million in total revenue for the year that ended June 30.

The year before, it lost about $935,000 on $8.7 million in revenue.

"Right now we are in growth mode," Dalton said. "That's expensive, but we're very excited."

He said M2Gen and Moffitt hope to expand the national network of hospitals that has helped build its database. So far, 95,000 patients have enrolled, agreeing to be followed for life and contacted when promising drugs surface.

"All cancer centers want to try to match their patients to the best therapies based on their clinical and molecular data. We happen to have a head start," said Dalton, who also directs Moffitt's personalized medicine institute. "The best thing to do now is to work with our colleagues and improve the effort with what they bring to the table."

Letitia Stein can be reached at lstein@tampabay.com or (727) 893-8330.

M2Gen partnership advances Moffitt Cancer Center vision for personalized medicine 03/01/13 [Last modified: Friday, March 1, 2013 10:53pm]
Photo reprints | Article reprints

© 2017 Tampa Bay Times

    

Join the discussion: Click to view comments, add yours

Loading...
  1. Hyde Park Village awaits two new clothing stores

    Retail

    TAMPA — Two new retailers, Social Status and Boho Hunter, are scheduled to open in Hyde Park Village this fall.

    Pictured is the exterior of Goody Goody, located in Tampa's Hyde Park Village.
[Times file photo]
  2. Ferguson attorney: Brown family settlement $1.5 million

    Nation

    ST. LOUIS — The $1.5 million awarded this week to the parents of Michael Brown is the latest of several large settlements involving black suspects who were killed by police, but it's far from the largest.

    In this Sept. 27, 2014, file photo, the parents of Michael Brown, Lezley McSpadden, left, and Michael Brown Sr., sit for an interview with The Associated Press in Washington. The city attorney in Ferguson, Missouri, said Friday  that the city's insurance company paid $1.5 million to settle a lawsuit filed by the family of Michael Brown. [AP photo]
  3. What happened when I took my dad to a Pitbull concert

    Music & Concerts

    TAMPA — "So, you know how you like Pitbull?" I asked my dad. "We can see him."

    Selfie of Divya Kumar and Anand Kumar at Pitbull/Enrique Iglesias concert.
  4. Sears closing another 20 stores

    Retail

    NEW YORK — Sears is closing another 20 stores as the ailing retailer tries to turn around its business.

    In a government filing Friday, real estate investment trust Seritage confirmed that Sears Holdings Corp. is closing another 20 stores, two of which are Kmart stores.
[AP file photo]
  5. A second mistrial: Jury deadlocks in Ohio cop's murder retrial

    Nation

    CINCINNATI — A mistrial was declared Friday in the murder retrial of a white University of Cincinnati police officer after the jury said it was hopelessly deadlocked on charges in the fatal traffic stop shooting of an unarmed black motorist.

    Former University of Cincinnati police officer Raymond Tensing, left, and his attorney Stew Mathews listen as Hamilton County Common Pleas Judge Leslie Ghiz tells the jury to continue deliberations after the jury said they are deadlocked during Tensing's trial on Friday in Cincinnati. [AP photo]